ReviewMedical2026
Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis.
Zolotov Y.; Slawek D.; Zhang C.; Ross J.; Levin F.; Dahmer S.; Cunningham C.; Starrels J.; Arnsten J.; Sohler N. · Substance use & addiction journal · 2026
Research summary
**Background & Methods**
This was an 18-month longitudinal cohort study of 223 adults (mean age 56.3 years, 54.3% female) newly certified for medical cannabis for chronic pain in New York. Participants completed structured DSM-5 diagnostic interviews and standardized questionnaires at baseline and every 3 months, with biweekly web-based self-reports of medical and unregulated cannabis use patterns.
**Key Findings**
• Adverse outcomes were infrequent over 18 months: 4.9% met DSM-5 criteria for cannabis use disorder (CUD) at one or more visits, 0.9% for opioid use disorder (OUD), 6.7% for hazardous alcohol use, 4.0% for cannabis diversion, and 1.8% for cannabis-related injuries.
• Participants with CUD demonstrated higher cannabis consumption (9.6 days of medical use and 5.3 days of unregulated use per 2-week period) compared to those without CUD (6.4 and 2.7 days respectively), suggesting a dose-response relationship.
• No consistent patterns emerged for other measured adverse outcomes, and emergency room visits were not prominently reported, indicating generally stable health status during follow-up despite regular cannabis use.
**Dosage & Administration**
Not reported.
**Safety & Adverse Effects**
The study did not specifically report cannabis-related adverse effects or side effects. Rather, it focused on structured adverse outcomes including CUD, OUD, hazardous alcohol use, diversion, injuries, and healthcare utilization. Cannabis-related injuries occurred in only 1.8% of participants over the 18-month period.
**Evidence Quality**
This study has several limitations: the relatively small sample size (n=223) and 18-month follow-up duration may be insufficient to detect rare or long-term risks. Self-reported data regarding cannabis use patterns and unregulated product use is subject to recall and social desirability bias. The cohort was geographically limited to New York and consisted primarily of middle-aged adults with chronic pain, limiting generalizability. The authors appropriately note that larger, longer-term studies may detect risks not captured here. Despite regular cannabis use reported throughout the study, the low prevalence of adverse outcomes suggests medical cannabis certification may be associated with relatively low risk in this population; however, the authors emphasize continued patient monitoring and education are warranted.
Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.
Journal
Substance use & addiction journal
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed
More recent cannabis research
This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.